Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$19.69−1.72 (-8.03%)
Close on Nov 17, 2026Market cap $1.87BP/E –Yield –
Replimune shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Replimune's shares outstanding was 105M at Sep 30, 2026. For fiscal 2026 it was 93M, up 15.2% from the year before. The highest annual figure on record is 93M in fiscal 2026.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | 93M | +15.2% |
| FY2025 | Mar 31, 2025 | 81M | +21.0% |
| FY2024 | Mar 31, 2024 | 67M | +14.4% |
| FY2023 | Mar 31, 2023 | 58M | +11.5% |
| FY2022 | Mar 31, 2022 | 52M | +12.9% |
| FY2021 | Mar 31, 2021 | 46M | +35.0% |
| FY2020 | Mar 31, 2020 | 34M | +47.7% |
| FY2019 | Mar 31, 2019 | 23M | +366.0% |
| FY2018 | Mar 31, 2018 | 5M | +0.1% |
| FY2017 | Mar 31, 2017 | 5M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | 105M | +14.4% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | 97M | +5.8% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | 96M | +5.1% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | 92M | +10.4% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | 92M | +17.0% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | 92M | +32.3% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | 91M | +36.3% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | 83M | +25.3% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | 79M | +18.0% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | 69M | +4.2% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | 67M | +1.0% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | 67M | +15.2% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | 67M | +21.6% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | 66M | +22.4% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | 66M | +25.6% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | 58M | +10.6% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | 55M | +5.2% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | 54M | +4.4% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | 53M | +1.6% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | 52M | +5.9% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | 52M | +18.3% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | 52M | +30.2% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | 52M | +33.1% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | 49M | +41.6% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | 44M | +39.0% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | 40M | +25.9% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | 39M | +23.3% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | 35M | +10.5% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | 32M | +28.9% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | 32M | +535.6% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | 31M | +532.2% |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | 32M | +533.9% |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | 25M | +393.6% |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | 5M | +0.2% |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | 5M | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | 5M | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | 5M | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | 5M | – |
See a number that looks wrong?